NeoGenomics, Inc.
NEO
NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $446.6M
$17.38
▼ -0.46%
P/E
-8.78
Mkt Cap
$446.6M
52-Wk Range
$7.07–$19.76
52-Week Range
$7.07 - $19.76
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 119.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Specialized cancer-focused testing expertise with multi-modal diagnostic capabilities
- Geographically diversified laboratory network across US, Europe, and Asia reducing operational risk
- Strategic alliance with Inivata Limited providing advanced molecular testing capabilities
- Established relationships with major pharmaceutical companies creating recurring revenue streams
- Comprehensive test menu reducing client need for multiple laboratory vendors
Bear Case
2 risks
- Above-average volatility (beta 1.7).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Rising global cancer incidence driving demand for diagnostic testing services
Value
Extreme premium - high expectations embedded
Momentum
Hot
+58.7% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying NEO right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 27, 2026
JUL 28, 2026
Reported EPS of $0.05 vs $0.03 consensus (+49.0% surprise). Revenue of $201.7M vs $196.9M expected (+2.4%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+49.0%
Revenue trend · last 8Q
—
+11%
+8%
+10%
+12%
+11%
+11%
+11%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$167.8M
$172.0M
$168.0M
$181.3M
$187.8M
$190.2M
$186.7M
$201.7M
Margins · last 8Q
Gross
45.6%
Operating
-4.8%
Profit
1.1%
Wall Street consensus
3 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Benchmark · Jul 24, 2026
vs Industry
How NEO stacks vs Medical - Diagnostics & Research
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related